Huanjia Zhang

The new guidance reflects the impact from China-related tariffs as well as dampening US grant funding, partially offset by the firm's mitigation actions.

GeneDx, which has been running a centralized lab, hopes to provide the new service to hospitals in the US and abroad that are already sequencing genomes in-house.

The service, aimed at healthcare professionals in Europe, promises to deliver diagnostic reports of microbial profiles within three to five days.

The Seattle-based firm booked $47.5 million in revenues during the fourth quarter while full-year revenues grew 5 percent to $179.0 million.

The company reported a 5 percent increase in Q4 2024 revenues and flat full-year revenues, but guided for 3 percent to 4 percent organic revenue growth in 2025.

Through close collaboration of more than 300 genomics and disease experts, the pan-European consortium solved more than 500 difficult cases. 

The University of Edinburgh spinout is leveraging an RNA normalization technology and analysis software to detect breast cancer early.

Revenues in the third quarter were driven by diagnostic exome and genome tests, which grew 76 percent in revenue and 46 percent in volume, prompting the firm to raise its 2024 guidance.

The company booked $10.60 billion in Q3 revenues, with flat year-over-year organic and core organic revenues.